 |
 |
 |
 |
 |
 |
 |
UNITED STATES |
|
Tercica was founded as a biotech company with a unique focus: to
develop and commercialize new products to patients with endocrine
diseases. Now part of the Ipsen group, we market Increlex, Somatuline
Depot, and Apokyn.
People with endocrine and neurologic diseases deserve better treatment options.
Our company is committed to fully embracing these underserved patient populations. That's why we offer distinct, novel products to help improve the lives of patients with these disorders.
We have exciting career opportunities for experienced people who share our passion for improving endocrine and neurologic health. Our company and professional relationships are guided by our vision, mission, and values.
Our company is committed to fully embracing these underserved patient populations. That's why we offer distinct, novel products to help improve the lives of patients with these disorders.
We have exciting career opportunities for experienced people who share our passion for improving endocrine and neurologic health. Our company and professional relationships are guided by our vision, mission, and values.
A message to the ALS Community from Tercica. Read more »
Increlex is the world's first long-term therapy for children with short stature due to severe Primary IGFD.
Our new product for adults with acromegaly simplifies treatment with a ready-to-use, prefilled syringe.
Learn about the first and only prescription medicine that reverses offepisode motor symptoms associated with advancing Parkinson's disease.